- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Riverain’s Chest X-Ray Comparison Tool Gets FDA Nod
Temporal Comparison software compares current and prior chest X-rays to help identify nodules that may be early-stage lung cancer.
Riverain Technologies, a Dayton, Ohio-based medical technology company, has received FDA 510(k) clearance for its Temporal Comparison software, which compares current and prior chest X-rays and can help identify nodules that may be early-stage lung cancer, the company announced.
The technology targets differences between the X-rays, drawing attention to what could be an emerging or enlarging tumor. The software aligns the two images to produce a difference image, which the company said allows radiologists to identify subtle changes more clearly.
In a study of 422 pairs of chest X-rays, 15 radiologists demonstrated an average of 12.4 percent improvement in sensitivity for actionable solitary pulmonary nodules using the software, compared to results viewing the X-rays side by side, the company said.
The software can be used with Riverain’s Bone Suppression software, which removes the bones from the image to make differences more conspicuous.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
